Phase 3Withdrawn
Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)
A Randomized, Double-blind, Placebo- and Active- Controlled, Multicenter Study of Rapastinel as Monotherapy in Major Depressive Disorder
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc (Industry)
- Conditions
- Depressive Disorder, Major
- Interventions
- Rapastinel; Vortioxetine; Placebo
- Ages
- adults, older adults
- Registry
- NCT03855865, EUCTR2018-000063-88
Full record on ClinicalTrials.gov
From the registry
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to 10 mg of Vortixetine and placebo in participants with major depressive disorder (MDD).
Primary outcomes
- Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at the End of the Double Blind Treatment Period (DBTP) (end of Week 6)
History
Primary completion
Last registry update
Started
Registered